Stoke Therapeutics (STOK) Other Non-Current Liabilities (2021 - 2026)

Stoke Therapeutics' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $991000.0 for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 47.12% year-over-year to $991000.0 in Q1 2026; TTM through Mar 2026 was $991000.0, a 47.12% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 53.95% from the prior year.
• Other Non-Current Liabilities slipped to $991000.0 in Q1 2026 per STOK's latest filing, from $1.1 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $4.9 million in Q4 2023 and bottomed at $959000.0 in Q3 2023.
• The 5-year median for Other Non-Current Liabilities is $2.5 million (2024), against an average of $2.6 million.
• Across the five-year window, Other Non-Current Liabilities plunged 73.43% in 2023 and jumped 218.04% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $3.0 million in 2022, then surged by 64.56% to $4.9 million in 2023, then plunged by 49.26% to $2.5 million in 2024, then tumbled by 53.95% to $1.1 million in 2025, then dropped by 13.15% to $991000.0 in 2026.
• Per Business Quant, the three latest STOK Other Non-Current Liabilities figures stand at $991000.0 (Q1 2026), $1.1 million (Q4 2025), and $1.9 million (Q3 2025).